Novo vs. KBP: How a $1.3B deal turned into an international legal fight

Biotech

Make a delay and accumulation of outstanding tasks Full stop
Biotech

Regeneron does 180 on 2seventy lymphoma CAR-T

Regeneron has given up on a CAR-T candidate acquired from 2seventybio last year, before it finished a phase 1/2 lymphoma study.
James Waldron Oct 23, 2025 10:57am
heart over ekg

Ventyx's CV drug rapidly reduces cardio risk biomarker

Oct 23, 2025 9:45am
Bringing clinical trials to the community a new model for precision enrollment

Bringing clinical trials to the community: a new model for precision enrollment

Oct 20, 2025 8:00am
Photo of an ax atop a pile of three logs

Roche axes 4 Chugai solid tumor assets in early-phase clear-out

Oct 23, 2025 4:53am
Redefining Biotech How AI and Real-World Data Power Patient-Centered Progress

Redefining Biotech: AI, RWD, and Patient-Centered Progress

Oct 20, 2025 8:00am
Cytomegalovirus CMV herpes herpesvirus virus

Moderna scraps congenital virus program after vax fails ph. 3

Oct 22, 2025 5:15pm